Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she has had discussions with NICE on their decision not to recommend using burosumab in the treatment of (a) X-linked hypophosphatemia and (b) related disorders in adults.

The Department has had no discussions with colleagues in the National Institute for Health and Care Excellence (NICE) regarding burosumab. NICE is an independent body and its recommendations are developed in accordance with its published methods and processes.

NICE has not yet published final guidance on the use of burosumab for the treatment of X-linked hypophosphataemia in adults. NICE’s draft guidance was recently subject to a public consultation and NICE will take the comments received fully into account in developing its final recommendations.